Ketamine is not PCP, but the two drugs are close chemical relatives with overlapping effects that lead to frequent confusion. Both belong to the arylcyclohexylamine family, both block the same type of brain receptor, and both can produce dissociative states, hallucinations, and analgesia. Ketamine was actually developed in the 1960s as a safer replacement for PCP in anesthesia, and the differences in how these two drugs behave in the body help explain why one remains a widely used medicine while the other was abandoned by mainstream medicine decades ago.
How Ketamine and PCP Are Chemically Related
Ketamine and PCP share a core chemical scaffold called the arylcyclohexylamine structure, which is an aromatic ring bonded to a cyclohexane ring with a nitrogen-containing group attached. PCP (phencyclidine) was the first drug in this family to be developed, originally introduced as an anesthetic in the 1950s. When PCP proved to cause severe emergence reactions, prolonged delirium, and psychotic episodes in surgical patients, researchers modified its structure to find something that worked similarly but wore off faster and caused fewer problems. The result was ketamine, which kept the dissociative anesthetic properties while being far more manageable in a clinical setting.
Structure-activity research on arylcyclohexylamines has shown that small modifications to the shared scaffold change potency and the quality of effects. Replacing parts of PCP’s piperidine ring with smaller nitrogen-containing groups (as ketamine does with a methylamine group) reduces potency at some receptor targets. Changes to the aromatic ring or the cyclohexyl ring shift the drug’s activity profile in predictable ways: hydroxyl groups on the cyclohexyl ring, for instance, reduce both potency and the ability to produce PCP-like effects, while the size of the aromatic ring influences how strongly the drug mimics PCP’s signature dissociation.1PubMed. Structure-activity relationships of arylcyclohexylamines as discriminative stimuli in pigeons These structural tweaks are the reason ketamine and PCP feel related but are not interchangeable.
The NMDA Receptor, Their Shared Target
The primary thing ketamine and PCP have in common pharmacologically is that both block the NMDA receptor, a type of glutamate receptor involved in learning, memory, pain signaling, and neural plasticity. Both drugs are “noncompetitive” blockers, meaning they physically plug the receptor’s ion channel rather than competing with glutamate for the binding site on the outside of the receptor. This NMDA blockade is responsible for most of the effects the two drugs share: dissociation, pain relief, amnesia, and at higher doses, anesthesia.2Brain Research. PCP and ketamine inhibit non-NMDA glutamate receptor mediated hsp70 induction
Because both drugs block NMDA receptors, both can also produce symptoms that closely resemble schizophrenia in healthy people, including hallucinations, disordered thinking, social withdrawal, and cognitive impairment. This observation has been hugely influential in psychiatry. Researchers have long used PCP and ketamine administration in animals as models for schizophrenia, and the two drugs are sometimes treated as interchangeable for that purpose.3PubMed. Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat The fact that blocking glutamate signaling produces psychosis-like symptoms contributed to the “glutamate hypothesis” of schizophrenia, which proposes that the disorder involves reduced NMDA receptor function.4PubMed Central. The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia
However, recent research has made clear that NMDA blockade alone does not explain everything either drug does. Ketamine’s antidepressant effect, for example, may not depend entirely on NMDA receptor inhibition. Studies suggest that downstream effects, including stimulation of another glutamate receptor type called AMPA and activation of signaling pathways that promote new synapse formation in the prefrontal cortex, play a critical role.5PubMed Central. Signaling pathways underlying the rapid antidepressant actions of ketamine An active metabolite of ketamine, hydroxynorketamine, has also attracted attention as a potential contributor to antidepressant effects through mechanisms that go beyond simple NMDA blockade.6PubMed Central. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism
Where Their Receptor Profiles Diverge
Once you look past the NMDA receptor, ketamine and PCP start behaving quite differently. One major area of divergence is their interaction with dopamine receptors, which matters because dopamine signaling is central to reward, motivation, and psychotic symptoms. Research measuring the affinity of both drugs for the high-affinity state of the dopamine D2 receptor has found that PCP binds the D2 receptor with much greater affinity than ketamine does. One study reported PCP’s binding affinity at the D2 high-affinity state at about 2.7 nanomolar, compared to 55 nanomolar for ketamine.7PubMed. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics That roughly 20-fold difference in D2 affinity likely contributes to PCP’s more intense and longer-lasting psychotic effects compared to ketamine’s.
The picture is actually debated, though. A separate study measuring receptor affinities using different methods found that ketamine and PCP had more similar binding profiles at dopamine and serotonin sites, with ketamine showing comparable affinity at NMDA and D2 sites and PCP showing similar affinity at NMDA and serotonin 5-HT2 sites.8PubMed. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for models of schizophrenia And another study found that neither ketamine’s enantiomers nor its metabolites had meaningful affinity for dopamine receptors or monoamine transporters at concentrations up to 10 micromolar.9PubMed Central. Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters The discrepancies probably reflect differences in experimental methods and the receptor states being measured. What is consistent across studies is that PCP has a broader and more pronounced effect on dopamine and serotonin systems than ketamine does, which tracks with the clinical observation that PCP produces more severe and unpredictable psychotic reactions.
Ketamine also differs from PCP in its interaction with GABA receptors in the cerebellum. At anesthetic concentrations, ketamine modulates a specific subtype of GABA-A receptor (containing alpha-6 and delta subunits) that PCP does not affect. Ketamine can even directly activate these receptors at higher concentrations. This difference likely contributes to ketamine producing greater central nervous system depression and sedation than PCP, which tends instead to produce agitation and stimulation at equivalent dissociative doses.10PubMed Central. Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits
Duration and the Experience of Being on Each Drug
One of the most practically important differences between ketamine and PCP is how long they last. An intramuscular injection of ketamine typically produces dissociative effects lasting 15 to 45 minutes, with full recovery within a couple of hours. PCP effects last vastly longer, often 4 to 6 hours for the acute phase, and in some cases residual cognitive disturbance or psychotic symptoms persist for days. This difference in duration was the original reason ketamine was developed: surgeons needed an anesthetic patients could recover from quickly, and PCP’s marathon-length effects made it impractical.
The subjective experience also differs in character. Ketamine at subanesthetic doses tends to produce dreamy dissociation, altered perception of time and space, and a floating or detached feeling. Users sometimes describe it as being in a bubble or observing themselves from outside. At anesthetic doses, it produces a unique state called “dissociative anesthesia,” where the person appears awake (eyes may be open, reflexes partially intact) but is unresponsive to pain and largely unconscious.
PCP, by contrast, is more likely to produce agitation, paranoia, and violent behavior, especially at moderate to high doses. Emergency room presentations for PCP intoxication are often dramatic, with patients exhibiting extreme combativeness, apparent insensitivity to pain, bizarre behavior, and sometimes severe self-harm. While ketamine can occasionally cause agitation during emergence from anesthesia, these reactions are far milder and less common than those associated with PCP. The gap in adverse psychiatric effects is wide enough that ketamine kept its place in medicine while PCP was dropped entirely from human clinical use by the late 1960s.
Medical Uses That Set Ketamine Apart
Ketamine’s clinical resume is long and growing. It was introduced commercially in 1970 as a rapid-acting nonbarbiturate general anesthetic, initially recommended for short surgical procedures.11PubMed Central. Ketamine: Current applications in anesthesia, pain, and critical care Since then, its applications have expanded to include pain management (particularly for chronic and neuropathic pain), sedation in emergency departments, battlefield anesthesia in resource-limited settings, and pediatric procedures where maintaining airway reflexes is important. More recently, ketamine and its S-enantiomer (esketamine, marketed as Spravato) have been approved for treatment-resistant depression and acute suicidal ideation, making it one of the few truly novel antidepressant mechanisms in decades.
Part of what makes ketamine useful in anesthesia is its unusual cardiovascular profile. Unlike most anesthetics that suppress the heart and lower blood pressure, ketamine stimulates the sympathetic nervous system, raising heart rate and blood pressure. It also causes bronchodilation, which makes it useful in patients with asthma or in emergency situations where maintaining blood pressure is critical. PCP has none of these clinical applications today. It was briefly marketed as Sernyl in the 1950s but pulled from human use, and it has no approved medical indication anywhere in the world.
Recent structural biology work has added another layer to the picture. A 2025 study demonstrated that ketamine directly activates opioid receptors, specifically the mu and kappa opioid receptors, at subanesthetic doses. When researchers blocked opioid receptors with naloxone or the selective kappa antagonist aticaprant, ketamine’s pain-relieving effect was completely abolished.12Nature Structural & Molecular Biology. Structural basis of opioid receptor activation by PCP and ketamine This opioid receptor activity adds to ketamine’s analgesic toolkit and may also be relevant to the ongoing debate about whether its antidepressant effect involves opioid pathways. PCP’s interaction with opioid receptors has been studied less extensively, and its clinical irrelevance means the question is mostly academic.
Neurotoxicity and Organ Damage
Both drugs share a neurotoxicity concern discovered in the early 1990s. NMDA receptor antagonists, including PCP, ketamine, and the research drug MK-801, can cause a distinctive pattern of damage to neurons in the rat brain, particularly in a region called the posterior cingulate/retrosplenial cortex. The damage starts as vacuolization (fluid-filled pockets inside neurons) and, at higher doses, progresses to cell death.13PubMed. NMDA antagonist neurotoxicity: mechanism and prevention These are sometimes called “Olney’s lesions” after the researcher who first described them.14PubMed Central. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801 The severity of this effect is dose-dependent and varies by drug; MK-801 is the most potent inducer, and the relevance to humans at clinical ketamine doses remains debated.15Drug Development Research. Pathomorphologic effects of N‐methyl‐D‐aspartate antagonists in the rat posterior cingulate/retrosplenial cerebral cortex: A review
Ketamine has a toxicity problem that PCP does not share at all: chronic recreational use can severely damage the bladder. People who use ketamine frequently over months or years can develop ulcerative cystitis, a painful condition involving inflammation and ulceration of the bladder lining. Symptoms include blood in the urine, drastically increased urination frequency, urgency, bladder pain, and in severe cases, the bladder can shrink to the point where it holds almost no urine.16Urological Science. A murderer of young bladders: Ketamine-associated cystitis This was first described as a distinct clinical entity in a 2007 case series and has become a well-recognized problem in countries where recreational ketamine use is common.17Urology. Ketamine-Associated Ulcerative Cystitis: A New Clinical Entity Chronic PCP users can develop a range of problems including persistent psychosis and cognitive impairment, but bladder destruction is not among them.
Abuse Potential and How Each Drug Hooks Users
Both ketamine and PCP carry abuse potential, but through somewhat different mechanisms and to different degrees. PCP is classified as a Schedule II controlled substance in the United States, reflecting the government’s view that it has high abuse potential with severe psychological or physical dependence. Ketamine is scheduled less restrictively as Schedule III, acknowledging abuse potential but with lower risk of severe dependence. Ketamine was added to Schedule III in 1999 after the DEA flagged its increasing presence in club drug scenes.18Bentham Science Publishers. Ketamine: From Prescription Anaesthetic to a New Psychoactive Substance
Research on ketamine’s enantiomers (mirror-image molecular forms) has revealed something interesting about its abuse liability. In rat self-administration studies, animals will readily self-administer (S)-ketamine but not (R)-ketamine, suggesting that abuse potential is concentrated in one molecular form.19Molecular Psychiatry. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability This has practical implications because esketamine (the S-enantiomer) is the form used in the FDA-approved nasal spray for depression, meaning the version with higher abuse potential is the one being prescribed for mental health. The R-enantiomer, arketamine, is being investigated as a potentially safer antidepressant alternative precisely because it appears less reinforcing.
PCP’s abuse profile is different and arguably more dangerous. Its longer duration, stronger dopamine effects, and tendency to produce unpredictable psychotic states mean that PCP binges can spiral into prolonged psychosis lasting days or weeks. PCP analogs continue to surface as novel psychoactive substances, with research showing that some of these analogs produce dopaminergic alterations that could enhance their addictive properties.20PubMed. The dopaminergic alterations induced by 4-F-PCP and 4-Keto-PCP may enhance their drug-induced rewarding and reinforcing effects: Implications for abuse
Drug Testing and Cross-Reactivity
A practical question people often have is whether ketamine will cause a positive result on a PCP drug test, and the answer is essentially no. A study evaluating five commercial urine immunoassays for PCP found that ketamine was not detected by any of them.21PubMed. Detectability of Dissociative Psychoactive Substances in Urine by Five Commercial Phencyclidine Immunoassays The structural differences between the two molecules are large enough that antibodies designed to detect PCP do not recognize ketamine. Interestingly, other PCP analogs like 3-MeO-PCP and 4-MeO-PCP did trigger PCP immunoassays, with cross-reactivity ranging from 1% to 143% depending on the assay. The dissociative drug methoxetamine (MXE), which is structurally closer to ketamine, showed only negligible cross-reactivity. So if you are using ketamine medically and are worried about a PCP-positive drug screen, that concern is unfounded. The tests are looking for different molecules.
Why Researchers Sometimes Treat Them as Interchangeable
If you read the scientific literature on schizophrenia or glutamate signaling, you will frequently encounter PCP and ketamine described as though they are the same thing. Phrases like “NMDA antagonists such as PCP/ketamine” appear in hundreds of papers, and animal models of schizophrenia freely substitute one for the other. This shorthand is understandable but sloppy. Studies directly comparing the two drugs in animals have found that their cognitive effects are not identical. One study showed that PCP and ketamine produced distinct patterns of cognitive disruption over time after a single dose, with the two drugs affecting attention and memory on different timescales.3PubMed. Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat Another found that ketamine was less effective than PCP at disrupting certain attention and working memory tasks in rodents.22PubMed. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory
The tendency to lump them together has consequences for how research findings are interpreted. If a study uses PCP to model schizophrenia in rats and the results are generalized to “NMDA antagonists,” readers might assume the same findings apply to ketamine at equivalent doses. But PCP’s longer duration, broader receptor profile, and stronger dopamine effects mean that chronic PCP administration in animals produces a different neurochemical picture than chronic ketamine would. Researchers working in this area increasingly acknowledge that PCP and ketamine models are not perfectly substitutable, even though both involve NMDA blockade as the starting point.
The S-Enantiomer and the PCP Binding Site
Ketamine is a racemic mixture, meaning the commercially available form contains equal parts of two mirror-image molecules: S-ketamine and R-ketamine. The S-enantiomer has roughly three to four times the anesthetic potency of the R-enantiomer, and this difference traces directly to the S-form’s higher affinity for the phencyclidine binding site on the NMDA receptor. That is a detail worth pausing on: the site where ketamine binds inside the NMDA receptor channel is literally called the “phencyclidine binding site” because PCP was the first drug found to occupy it. When clinicians talk about ketamine’s potency at the PCP binding site, they are describing the physical slot inside the receptor that PCP was named for. The two drugs plug the same hole, but ketamine does so more briefly and with less collateral receptor activity elsewhere in the brain.
This distinction between enantiomers has shaped the development of ketamine-based therapies. Esketamine (the S-form) was chosen for the nasal spray formulation approved for depression partly because of its greater potency, allowing lower doses. But as noted above, the S-form also carries greater abuse liability. R-ketamine (arketamine) appears to have stronger antidepressant effects than S-ketamine in some animal models despite weaker NMDA binding, which has added fuel to the debate about whether NMDA blockade is really the mechanism behind ketamine’s mood effects.23PubMed Central. Ketamine: NMDA Receptors and Beyond If R-ketamine ultimately proves effective in humans with lower abuse risk, the irony would be that the version of ketamine least like PCP is the one that works best as an antidepressant.